Although mechanisms, such as the presence of mutations in codons 12 and 13 of the K-Ras gene65 exist that render tumor cells inherently resistant to EGFR-targeted therapies, acquired resistance is a more widespread clinical problem. This evidence concerns the gene KRAS and neoplasm.